Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLN-346 in Hyperuricemic Subjects With Gout and CKD
NCT04987294Phase 2Terminated
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ALLN-346 in gout, hyperuricemia, sponsored by Allena Pharmaceuticals, Inc.. Started Sep 2022; status: terminated.
02
Drugs
ALLN-346
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04987294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987294.